Version history

{
  "session_id": "sess_SDA-2026-04-04-gap-tau-prop-20260402003221_20260412-085642",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"Trans-synaptic transfer is the dominant mechanism of tau pathology propagation in connected brain networks\",\n      \"mechanism\": \"Pathological tau seeds are released presynaptically via synaptic vesicle cycling, cross the synaptic cleft, and are endocytosed by the postsynaptic neuron where they templated native tau into misfolded aggregates.\",\n      \"target_gene\": \"MAPT\",\n      \"confidence_score\": 0.78,\n      \"novelty_score\": 0.52,\n      \"feasibility_score\": 0.58,\n      \"impact_score\": 0.82,\n      \"composite_score\": 0.70,\n      \"testable_prediction\": \"Conditional deletion of tau in donor neurons will halt trans-synaptic pathology propagation in a neuronal circuitry model, while preserving normal tau function in recipient neurons.\",\n      \"skeptic_concern\": \"Current evidence remains correlative; definitive proof requires demonstrating that purely postsynaptic uptake of synaptic inputs is insufficient for templating in vivo.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Extracellular vesicles constitute a synapse-independent tau propagation pathway with distinct biophysical properties\",\n      \"mechanism\": \"Tau aggregates are packaged into exosomes and ectosomes that fuse with recipient neuron membranes via tetraspanin-mediated endocytosis, delivering seed-competent material across non-synaptic distances.\",\n      \"target_gene\": \"CD9, CD81\",\n      \"confidence_score\": 0.62,\n      \"novelty_score\": 0.68,\n      \"feasibility_score\": 0.45,\n      \"impact_score\": 0.74,\n      \"composite_score\": 0.64,\n      \"testable_prediction\": \"Selective depletion of neuron-derived exosomes via NPC1-mediated blockade will reduce inter-hemispheric tau spreading in human iPSC xenograft models without affecting synaptic transfer.\",\n      \"skeptic_concern\": \"EV preparations remain heterogeneous; current markers cannot isolate pathogenic tau-carrying vesicles from abundant physiological exosomes, confounding causal interpretation.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Synergistic intervention targeting seed formation, trans-synaptic spread, and neuronal uptake exceeds single-target efficacy\",\n      \"mechanism\": \"Combining blood-brain barrier-penetrant anti-tau antibodies to neutralize extracellular seeds, small molecules to inhibit synaptic release (e.g., syntilin), and receptor antagonists (e.g., LDL family blockers) for uptake blockade will achieve additive therapeutic benefit.\",\n      \"target_gene\": \"LRP1, LDLR\",\n      \"confidence_score\": 0.55,\n      \"novelty_score\": 0.48,\n      \"feasibility_score\": 0.65,\n      \"impact_score\": 0.85,\n      \"composite_score\": 0.61,\n      \"testable_prediction\": \"Triple pathway inhibition will produce >60% reduction in spreading metrics in functional imaging readouts compared to <25% for any single intervention in a human-synaptic-connectivity mouse model.\",\n      \"skeptic_concern\": \"Combination therapies increase off-target risk and regulatory complexity; pharmacokinetic interactions between mechanistically distinct compounds are poorly characterized.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"Prion-like templating of native tau by pathological seeds is mechanistically established\",\n    \"Neural network activity and synaptic connectivity dictate the anatomical pattern of spreading\",\n    \"Targeting extracellular tau species represents the most immediately druggable intervention point\"\n  ],\n  \"dissent_points\": [\n    \"Trans-synaptic transfer versus EV-mediated spread as the dominant in vivo pathway remains unresolved\",\n    \"Whether physiological tau release contributes to pathological seeding is contested\",\n    \"The relative contribution of synaptic versus non-synaptic mechanisms varies across anatomical regions and disease stages\"\n  ],\n  \"debate_summary\": \"The debate converged on tau propagation being a multi-modal process where trans-synaptic transfer provides the anatomical scaffold for network-level spreading while EV-mediated mechanisms enable longer-range dissemination. The skeptic's call for molecular specificity—particularly identifying definitive receptors for uptake and markers for pathogenic vesicles—represents the critical experimental gap that must be addressed to move beyond correlative evidence. The expert emphasized that clinical translation of any mechanism requires human-synaptic-connectivity models that current mouse systems inadequately recapitulate.\"\n}\n```",
  "tokens_used": "1109"
}